Home | Welcome to Contract Pharma   
Last Updated Friday, November 28 2014
Print

Novo Nordisk Exits Inflammatory R&D



Published September 3, 2014
Related Searches: R&D
Novo Nordisk has decided to discontinue all R&D activities within inflammatory disorders and will increase efforts within diabetes prevention and treatment, obesity and diabetes complications.
 


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On